Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.03 to $1.18
• 52-Week Range: N/A
• Volume: 53.64 million shs
• Average Volume: 509,433 shs
• Market Capitalization: $857 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Accelerate Diagnostics Stock Analysis - MarketRank™

Accelerate Diagnostics scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Accelerate Diagnostics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AXDX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accelerate Diagnostics does not currently pay a dividend.

Dividend Growth

Accelerate Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.62

Short Interest

There is no current short interest data available for AXDX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,302.00 in company stock.

Percentage Held by Insiders

43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

AXDX Stock Analysis - Frequently Asked Questions

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.13. The medical research company earned $2.82 million during the quarter, compared to the consensus estimate of $3 million.

When did Accelerate Diagnostics' stock split?

Accelerate Diagnostics shares reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Accelerate Diagnostics' major shareholders?

Top institutional shareholders of Accelerate Diagnostics include Griffin Asset Management Inc. (3.38%) and Simplex Trading LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling.
View institutional ownership trends.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/20/2025
• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AXDX
• CIK: 727207
• Web: acceleratediagnostics.com
• Phone: (520) 365-3100
• Fax: 520-269-6580
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.62 million
• Net Margins: -471.83%
• Pretax Margin: -444.14%
• Return on Equity: N/A
• Return on Assets: -191.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.50
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $11.70 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 25,210,000
• Free Float: 14,125,000
• Market Cap: $857 thousand
• Optionable: Optionable
• Beta: 0.22